BCM
KRON

Bluefin Capital Management’s Kronos Bio KRON Stock Holding History

Bluefin Capital Management’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$25.1K Hold
25,100
– – 0.01% 99
2024
Q2 		$31.1K Hold
25,100
– – 0.01% 85
2024
Q1 		$32.6K Hold
25,100
– – 0.01% 108
2023
Q4 		$31.1K Buy
+25,100
New +$27.8K ﹤0.01% 158

Other funds holding KRON

VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCIG
Partners Capital Investment Group Boston, Massachusetts $2.83B AUM 20.31% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bluefin Capital Management's KRON Position: Q3 2024 in Review

Bluefin Capital Management held its Kronos Bio (KRON) position steady in Q3 2024 at 25,100 shares worth $25.1K. The position accounts for 0.01% of the portfolio, ranked #99.

Bluefin Capital Management first reported a position in KRON in Q4 2023 and has held it in 4 quarters since. The position peaked at $32.6K in Q1 2024. 53 funds tracked by Wall St. Rank hold KRON as of Q3 2024.

  • Bluefin Capital Management held 25,100 shares of Kronos Bio worth $25.1K as of Q3 2024.
  • Bluefin Capital Management left its Kronos Bio share count unchanged in Q3 2024.
  • Kronos Bio made up 0.01% of Bluefin Capital Management's portfolio in Q3 2024, its #99 holding.
  • Bluefin Capital Management first reported a position in Kronos Bio in Q4 2023 and has held it in 4 quarters since.
  • Bluefin Capital Management's Kronos Bio position peaked at $32.6K in Q1 2024.
  • 53 funds tracked by Wall St. Rank held Kronos Bio as of Q3 2024.

Based on Bluefin Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.